Skip to main content
Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
26.74
-0.38 (-1.40%)
At close: Apr 28, 2026, 4:00 PM EDT
26.72
-0.02 (-0.07%)
After-hours: Apr 28, 2026, 4:10 PM EDT

Oculis Holding AG Revenue

In the year 2025, Oculis Holding AG had annual revenue of 1.20M CHF with 74.78% growth. Oculis Holding AG had revenue of 411.00K in the quarter ending December 31, 2025, with 13,600.00% growth.

Revenue (ttm)
1.20M CHF
Revenue Growth
+74.78%
P/S Ratio
1,045.59
Revenue / Employee
19,983 CHF
Employees
60
Market Cap
1.58B USD

Revenue Chart

* This company reports financials in CHF.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20251.20M513.00K74.78%
Dec 31, 2024686.00K-197.00K-22.31%
Dec 31, 2023883.00K-29.00K-3.18%
Dec 31, 2022912.00K-48.00K-5.00%
Dec 31, 2021960.00K-33.00K-3.32%
Dec 31, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Immunocore Holdings 400.02M
Monte Rosa Therapeutics 123.67M
Intellia Therapeutics 67.67M
Immatics 56.67M
Agios Pharmaceuticals 54.03M
Nanobiotix 38.27M
Generate Biomedicines 31.89M
Revenue Rankings

OCS News

More News